These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 20587645)

  • 61. Augmented anti-angiogenesis activity of polysulfated heparin-endostatin and polyethylene glycol-endostatin in alkali burn-induced corneal ulcers in rabbits.
    Li ZN; Yuan ZF; Mu GY; Hu M; Cao LJ; Zhang YL; Ge MX
    Exp Ther Med; 2015 Sep; 10(3):889-894. PubMed ID: 26622410
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Inhibitory effect of polysulfated heparin endostatin on alkali burn induced corneal neovascularization in rabbits.
    Li ZN; Yuan ZF; Mu GY; Hu M; Cao LJ; Zhang YL; Liu L; Ge MX
    Int J Ophthalmol; 2015; 8(2):234-8. PubMed ID: 25938033
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Inhibition of neutrophil collagenase/MMP-8 and gelatinase B/MMP-9 and protection against endotoxin shock.
    Qiu Z; Chen J; Xu H; Van den Steen PE; Opdenakker G; Wang M; Hu J
    J Immunol Res; 2014; 2014():747426. PubMed ID: 25762310
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Trans-3,4,5,4'-tetramethoxystilbene, a resveratrol analog, potently inhibits angiogenesis in vitro and in vivo.
    Chen LK; Qiang PF; Xu QP; Zhao YH; Dai F; Zhang L
    Acta Pharmacol Sin; 2013 Sep; 34(9):1174-82. PubMed ID: 23770989
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Studies of poly(ethylene glycol) modification of HM-3 polypeptides.
    Zhou K; Zheng X; Xu HM; Zhang J; Chen Y; Xi T; Feng T
    Bioconjug Chem; 2009 May; 20(5):932-6. PubMed ID: 19413309
    [TBL] [Abstract][Full Text] [Related]  

  • 66. In vivo anti-tumor activity of polypeptide HM-3 modified by different polyethylene glycols (PEG).
    Liu Z; Ren Y; Pan L; Xu HM
    Int J Mol Sci; 2011; 12(4):2650-63. PubMed ID: 21731464
    [TBL] [Abstract][Full Text] [Related]  

  • 67. In vivo pharmacokinetics, immunogenicity and mechanism of PEGylated antitumor polypeptide.
    Liu Z; Li W; Xu HM; Huang X; Pan L; Ren Y; Yang Y; Li Y; Pu C; Zhang C
    Curr Pharm Des; 2012; 18(12):1655-62. PubMed ID: 22283767
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Effects of cloned tumstatin-related and angiogenesis-inhibitory peptides on proliferation and apoptosis of endothelial cells.
    Zhang GM; Zhang YM; Fu SB; Liu XH; Fu X; Yu Y; Zhang ZY
    Chin Med J (Engl); 2008 Nov; 121(22):2324-30. PubMed ID: 19080341
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Enhanced anti-angiogenesis and anti-tumor activity of endostatin by chemical modification with polyethylene glycol and low molecular weight heparin.
    Tan H; Yang S; Liu C; Cao J; Mu G; Wang F
    Biomed Pharmacother; 2012 Dec; 66(8):648-54. PubMed ID: 23122594
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Endostatin derivative angiogenesis inhibitors.
    Zheng MJ
    Chin Med J (Engl); 2009 Aug; 122(16):1947-51. PubMed ID: 19781376
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Site-specific modification of anti-angiogenesis peptide HM-3 by polyethylene glycol molecular weight of 20 kDa.
    Zhu B; Xu HM; Zhao L; Huang X; Zhang F
    J Biochem; 2010 Sep; 148(3):341-7. PubMed ID: 20587645
    [TBL] [Abstract][Full Text] [Related]  

  • 72.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 73.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 74.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 75.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 76.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 77.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 78.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 79.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 4.